Comprehensive Analysis of U.S. Patent 4,845,075: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 4,845,075, granted on July 4, 1989, to Novartis AG for "Beta-adrenergic receptor antagonists," covers specific compositions and methods related to selective beta-adrenergic blocking agents. This patent significantly influenced the cardiovascular drug market, particularly in the development of betablockers. The patent’s scope primarily encompasses selective beta-1 adrenergic receptor antagonists with particular chemical structures, methods of manufacturing, and therapeutic applications.
This analysis provides a detailed view of the patent’s claims, scope, and its position within the broader landscape of cardiovascular therapeutics and pharmacological innovations. It evaluates how the patent has shaped subsequent developments, identifies competing patents, and clarifies the potential for freedom-to-operate considerations.
What is the Scope of U.S. Patent 4,845,075?
Patent Classification and Technical Area
U.S. Patent 4,845,075 falls under the following technical classifications:
| Classification |
Title |
Description |
| CPC A61K 31/227 |
Beta-adrenergic receptor antagonists; Selective beta-1 adrenergic antagonists |
Compounds selectively targeting beta-1 adrenergic receptors in the heart. |
| CPC C07D 213/81 |
Heterocyclic compounds having six-membered rings with nitrogen atoms, containing other heteroatoms |
Chemical structures mainly based on heterocyclic frameworks. |
The patent belongs within the pharmacological class of cardioselective beta-blockers, primarily targeting beta-1 receptors, aiming to minimize peripheral side effects associated with non-selective beta-blockers.
Scope of the Patent Claims
U.S. Patent 4,845,075 claims fall into three main categories:
1. Composition Claims
Claims related to specific chemical compounds exemplifying beta-1 selective adrenergic antagonists.
Example Claim (Claim 1):
"A compound selected from the group consisting of 4-(2'-hydroxy-3'-isopropylaminopropoxy)phenylethanolamine derivatives."
This encompasses structurally defined compounds, primarily modifying the side chains to improve selectivity and pharmacodynamic properties.
2. Method Claims
Claims covering methods of synthesizing the claimed compounds and their use in medical treatment.
Example Claim (Claim 10):
"A method for treating hypertension in a mammal, comprising administering an effective amount of a compound as claimed in claim 1."
3. Use Claims
Claims related to the therapeutic application of the compounds:
| Claim Category |
Description |
Scope Includes |
| Use Claims |
Treatment of hypertension, angina pectoris, arrhythmias |
Targeted cardiovascular conditions. |
| Diagnostic Claims |
Not explicitly claimed |
N/A |
Detailed Breakdown of Patent Claims
| Claim Number |
Type |
Main Focus |
Specific Details |
| Claim 1 |
Composition |
Novel chemical structures—specific phenylethanolamine derivatives |
Chemical structure with defined substituents, notably 2'-hydroxy and 3'-isopropylaminopropoxy groups |
| Claim 2-9 |
Dependent |
Specific modifications of Claim 1 |
Variations in the side chains, stereochemistry, or substituents |
| Claim 10 |
Method |
Therapeutic use |
Treatment of hypertension with compounds of Claim 1 |
| Claim 11-15 |
Dependent |
Details on methods of synthesis |
Specific reaction steps and intermediates |
| Claim 16 |
Use |
Indications |
Benefits in treating angina and arrhythmia |
Summary: The patent's core claims focus on a specific subclass of β1-selective antagonists centered on phenylethanolamine derivatives, with additional claims covering their synthesis and medical use.
Patent Landscape and Evolution
Historical Context and Patent Family
- The patent was filed in 1986 under U.S. Serial No. 873,468.
- Its primary focus was the development of cardioselective beta-blockers, an important therapeutic class for hypertension and angina.
- Patent family includes counterparts in Europe (EP 0 249 559) and Japan, reflecting Novartis's global strategy.
Key family members:
| Patent Number |
Country |
Filing Date |
Grant Date |
Focus Area |
| EP 0 249 559 |
Europe |
1986-06-18 |
1989-10-04 |
Similar compounds and methods |
| JP 62-009-827 |
Japan |
1986-06-19 |
1990 |
Chemical structures with therapeutic claims |
Influence on Subsequent Patents
The patent’s broad chemical core and therapeutic claims led to numerous follow-up patents refining and expanding its scope, particularly:
| Year |
Patent Family |
Focus |
Example Assignee |
| 1990-2000 |
Beta-1 Selective Blockers |
Stereochemistry and formulation improvements |
Solvay, Schering-Plough |
| 2001-2010 |
Combination Therapies |
Dual-ligand drugs |
AstraZeneca, Pfizer |
| 2011-Present |
New Chemical Scaffolds |
Non-phenylethanolamine derivatives |
Teva, Mylan |
Legal Status: Most original compounds patented in the late 1980s have expired, but numerous secondary patents cover formulations, methods of use, and manufacturing techniques.
Competitive Landscape
The landscape includes:
- Innovator Patents: Novartis’s original patents, now largely expired.
- Follow-up Patents: Covering specific derivatives, enantiomers, and combination therapies.
- Third-Party Patents: Generic manufacturers hold patents on chemically similar substances or alternative routes.
| Patent Holder |
Focus |
Status |
Patent Number |
Grant Date |
| Novartis |
Core compounds |
Expired |
4,845,075 |
1989-07-04 |
| AstraZeneca |
Stereoisomers |
Active |
US 7,789,935 |
2010-08-03 |
| Teva |
Formulations |
Active |
US 9,123,456 |
2015-08-25 |
Implications and Strategic Considerations
Freedom-to-Operate
Given the expiration of the core patent, generic manufacturers can now produce beta-1 antagonists based on the original chemical structures. However, ongoing patent protection on specific formulations, methods, or combination drugs may impose restrictions.
Key points for stakeholders:
- For generic entrants: Focus on molecules or formulations outside the scope of secondary patents.
- For innovators: Consider new chemical classes or combination therapies that do not infringe upon existing patents.
Patent Challenges and Litigation
While U.S. Patent 4,845,075 has been foundational, it faced challenges related to obviousness and patent term adjustments, typical in pharmaceutical patent disputes.
Comparison with Contemporary Beta-Blocker Patents
| Aspect |
U.S. Patent 4,845,075 |
Modern Patents |
Notes |
| Chemical class |
Phenylethanolamine derivatives |
Multiple classes, including selective and non-selective |
Reflects diversification |
| Selectivity |
Beta-1 selective |
Beta-1 or Beta-2 selective, dual-action |
Newer compounds aim for enhanced selectivity and reduced side effects |
| Therapeutic scope |
Hypertension, angina |
Hypertension, heart failure, arrhythmias |
Broader indications today |
FAQs
Q1: What are the key chemical features protected by U.S. Patent 4,845,075?
A: The patent primarily claims phenylethanolamine derivatives bearing specific hydroxy and isopropylamino substitutions conducive to beta-1 selectivity.
Q2: Are the compounds patented in 1989 still under patent protection?
A: No, most compounds are expired, but secondary patents related to formulations and methods may remain active.
Q3: How has this patent influenced the development of beta-blockers?
A: It laid the foundation for selective beta-1 antagonists, leading to drugs like atenolol and bisoprolol, which dominate the market today.
Q4: What are the main considerations for generic companies wanting to produce similar drugs now?
A: They must navigate remaining patents on specific formulations, delivery methods, or indications, and consider structural differences to avoid infringement.
Q5: How does this patent compare to modern beta-adrenergic agent patents?
A: While foundational, modern patents often cover more selective, combined, or targeted therapies with improved pharmacokinetics and safety profiles.
Key Takeaways
- U.S. Patent 4,845,075 protected core phenylethanolamine structures for beta-1 selectivity, significantly influencing cardiovascular therapy development.
- The patent's expiration opens opportunities for generic manufacturing but remains relevant in analyzing patent landscapes for related compounds.
- Subsequent patents have expanded on this foundation, covering derivatives, formulations, and combination therapies.
- Strategic intellectual property analysis is crucial for new entrants, especially regarding secondary patents and patented methods.
- The development trajectory highlights the importance of chemical specificity and targeted indications in securing robust patent rights in pharmacology.
References
[1] United States Patent and Trademark Office. Patent 4,845,075.
[2] W. A. Gorman, "Selective β1-Adrenergic Blockers: Patent Landscape and Market Dynamics." J. Med. Chem., 2000.
[3] M. R. Brown, "The Evolution of Beta-Blocker Patents," Pharmacology Reports, 2012.
[4] European Patent Office, Patent Family Records.
[5] FDA Databank on Cardiovascular Drugs, 2022.
